Adalimumab, Infliximab and Etanercept Biosimilars Market Outlook Through 2030: Understanding The Growth Opportunity
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Adalimumab, Infliximab and Etanercept Biosimilars Market Size Forecast: How Big Could The Market Get By 2030?
The adalimumab, infliximab and etanercept biosimilars market size has experienced rapid expansion in recent years. This market is projected to expand from $4.96 billion in 2025 to $5.47 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this growth has been driven by factors such as the increasing prevalence of autoimmune diseases, the high expense of originator biologics, rising recognition of biosimilars, advancements in biologics manufacturing processes, and favorable government policies.
The adalimumab, infliximab, and etanercept biosimilars market is anticipated to experience rapid expansion over the next few years. It is projected to grow to $8.05 billion in 2030, achieving a compound annual growth rate (CAGR) of 10.1%. This expected growth during the forecast period can be attributed to several factors, including advancements in precision medicine, the expansion of biosimilar pipelines, rising healthcare expenditure, increasing adoption of digital health solutions, and a growing geriatric population. Major trends foreseen in this period include enhanced biosimilar adoption and market penetration, the development of cost-effective TNF-alpha inhibitors, supportive regulatory approvals and policy frameworks, the expansion of hospital and retail pharmacy networks, and the implementation of personalized treatment protocols.
Get A Free Sample Report With In-Depth Market Insights:
Adalimumab, Infliximab and Etanercept Biosimilars Market Growth Catalysts And Demand Drivers
The increasing occurrence of autoimmune diseases is projected to stimulate the expansion of the adalimumab, infliximab, and etanercept biosimilars market in the coming years. Autoimmune disease refers to health conditions or disorders resulting from immune system dysfunction, where the body’s immune cells attack its own healthy cells. Adalimumab, infliximab, and etanercept are biological drugs containing tumor necrosis factor (TNF) alpha inhibitors, utilized for treating various autoimmune diseases. For instance, in 2023, according to Johns Hopkins University, a US-based private research university, around 10 million people in the US, representing 3% of the population, were affected by all autoimmune illnesses. Therefore, the rising prevalence of autoimmune diseases is a significant driver for the growth of the adalimumab, infliximab, and etanercept biosimilars market.
Adalimumab, Infliximab and Etanercept Biosimilars Market Segment Analysis Spotlighting Growth Areas
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –
1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development
Adalimumab, Infliximab and Etanercept Biosimilars Market Trends Shaping Long-Term Demand
Major companies in the adalimumab, infliximab, and etanercept biosimilars market are prioritizing technological advancements, such as high-concentration, citrate-free biosimilars, to meet the increasing demand for more patient-friendly formulations, enhanced affordability, and expanded market access. These advanced high-concentration, citrate-free versions possess the same therapeutic monoclonal antibody structure as traditional biosimilars but provide a more comfortable injection experience, with less sting on administration. This potentially improves patient adherence and switching rates compared to conventional buffered formulations. As an illustration, in June 2023, Celltrion USA, a US-based biopharmaceutical company, launched Yuflyma (adalimumab-aaty), a citrate-free, high-concentration (100 mg/mL) biosimilar of Humira (adalimumab), developed to deliver identical potency and efficacy in a more patient-friendly format. Yuflyma offers the full therapeutic effect of adalimumab, with the added benefit of improved tolerability due to reduced injection pain, fostering broader uptake in the immunology market, particularly for chronic inflammatory diseases.
Adalimumab, Infliximab and Etanercept Biosimilars Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad
View The Full Adalimumab, Infliximab and Etanercept Biosimilars Market Report:
Adalimumab, Infliximab and Etanercept Biosimilars Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2025. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
